Optimer (OPTR) Announces Add-on Payment From Medicare & Medicaid Services for its DIFICID
- Top 10 News for 4/25 - 4/29: Merger Madness!; Valeant Hies New Boss; Icahn's Exit of Apple Could be Telling Sign
- Wall Street falls as earnings weigh; Dow, S&P up for month
- Amazon.com (AMZN) Tops Q1 EPS by 49c; Issues Q2 Outlook
- Exclusive: Yahoo's bidder shortlist points to cash deal -sources
- Yen posts biggest weekly gain since 2008, stocks slip
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for DIFICID tablets administered in the inpatient setting to treat Clostridium difficile-associated diarrhea (CDAD). Introduced in 2001, the CMS NTAP program is designed to support timely access of innovative therapies used to treat Medicare beneficiaries in the inpatient setting. The NTAP program is only available to new technologies demonstrating a substantial clinical improvement and meeting specific cost thresholds. The NTAP payment will provide hospitals with a payment, in addition to the standard-of-care DRG reimbursement, of up to 50% of the cost of DIFICID for a period of two to three years, effective in the fiscal year starting on October 1, 2012. For 2013, CMS has assigned a maximum payment of $868.00. The NTAP payment is available to hospitals only for individual patient cases that are more costly than the average DRG charges.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: FDA Approves First Generic Crestor (AZN)
- AstraZeneca (AZN) Receives Positive EMA CHMP Opinion on Zavicefta as cIAI, cUTI, and HAP Treatment
- AbbVie (ABBV), Galapagos (GLPG) Enter Expanded CF Collaboration
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!